Your MS is driven by specific neuroinflammatory pathways. Understanding whether you're Th1, Th17, or B-cell dominant helps you start with the right high-efficacy DMT from day one.
Standard MS treatment follows an escalation approach: start with first-line DMTs like Copaxone or Avonex, wait 12-18 months to see if they work, then escalate to high-efficacy therapies if they fail. Meanwhile, new lesions form and disability accumulates.
The question is: If you're going to need Ocrevus, Tysabri, or Mavenclad anyway, why waste 18 months on therapies that won't control YOUR disease? The answer lies in understanding your neuroinflammatory pathways.
Understanding which pathway is driving YOUR neuroinflammation
What's happening: Your immune system's Th1 cells release interferon-gamma (IFN-γ), which activates macrophages to attack your myelin. This pathway creates inflammation that damages the protective coating around your nerves.
Think of it like this: Your immune system has activated a "seek and destroy" program against myelin. Th1 cells are sending signals that recruit damage-causing cells to your brain and spinal cord.
What we test:
IFN-γ, IL-2, TNF-α, IL-12
If this is YOUR pathway, consider these DMTs:
Tysabri (natalizumab), Gilenya (fingolimod), Mavenclad (cladribine)
What's happening: Th17 cells produce IL-17, which breaks down the blood-brain barrier and allows inflammatory cells to flood into your central nervous system. This pathway is associated with more aggressive, relapsing MS.
Think of it like this: IL-17 is like breaking down the security gates around your brain, allowing damaging immune cells to rush in. The more IL-17, the more breaches in your defenses.
What we test:
IL-17A, IL-17F, IL-23, IL-6, IL-21
If this is YOUR pathway, consider these DMTs:
Mavenclad (cladribine), Kesimpta (ofatumumab), Tysabri (natalizumab)
What's happening: B-cells (not just antibodies) play a major role in MS by presenting antigens, producing inflammatory cytokines, and organizing inflammatory responses in your CNS. They're actively driving your disease progression.
Think of it like this: B-cells are like project managers coordinating the attack on your myelin. Remove the project managers (B-cells), and the attack becomes disorganized and less effective.
What we test:
CD19+ B-cells, memory B-cells, BAFF/BLyS, CXCL13, oligoclonal bands
If this is YOUR pathway, these DMTs target it:
Ocrevus (ocrelizumab), Kesimpta (ofatumumab), Briumvi (ublituximab) - B-cell depletion therapies
Every new lesion and every bit of brain volume loss is permanent. High-efficacy DMTs reduce annual relapse rates by 70-90% vs 30% for first-line therapies.
Studies show patients who start with high-efficacy DMTs have better disability outcomes 5-10 years later compared to those who escalate gradually.
Early, aggressive treatment preserves brain volume and function. The inflammatory phase of MS is when you have the most opportunity to change the disease course.
Research shows that immune profiling can predict DMT response. Patients with high B-cell activity respond better to B-cell depleting therapies. Those with Th17 dominance benefit from therapies targeting IL-17 pathways. It's not a crystal ball, but it's far better than guessing.
A marker of active neurological damage. Elevated NfL means your disease is currently destroying neurons. This helps determine if your current DMT is working or if you need to switch.
Determines your risk of PML (progressive multifocal leukoencephalopathy) if considering Tysabri. JC-negative patients have extremely low PML risk, while JC-positive patients need careful monitoring.
Rules out MOG-antibody disease and Neuromyelitis Optica Spectrum Disorder (NMOSD), which look like MS but require completely different treatments. Critical for accurate diagnosis.
Don't waste 18 months on first-line therapies. Start with the DMT most likely to work for YOUR disease.
See MS Testing Options →